In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

TriVascular brings in $60mm through its Series C round

14 Jul 2010

Executive Summary

TriVascular Inc. (stents for endovascular aortic repair) has raised $60mm through its Series C venture round. New backer Pinnacle Ventures led the financing and was joined by current shareholders New Enterprise Associates, Delphi Ventures, MPM Capital, and Kearny Venture Partners. Pinnacle and NEA will each contribute one board member. The money will support the launch TriVascular's Ovation abdominal stent graft system in Europe, clinical research performed on three continents for projects that include the Ovation thoracic stent graft system, and next-generation product development. The company has brought in $155mm since it was restarted in 2008 after being acquired from Boston Scientific.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By